WHO ICTRP trial
Effects of acipimox on free fatty acids and urinary albumin/creatinine ratio in…
ChiCTR2000040140 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000040140 |
|---|---|
| Public title | Effects of acipimox on free fatty acids and urinary albumin/creatinine ratio in patients with different glucose tolerance and hypertriglyceridemia |
| Scientific title | Effects of acipimox on free fatty acids and urinary albumin/creatinine ratio in patients with different glucose tolerance and hypertriglyceridemia |
| Primary sponsor | Shougang Hospital of Peking University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Diabetic nephropathy |
| Interventions | Experimental group:acipimox;Control group:Lifestyle intervention |
| Registration date | Nov 22, 2020 |
| Target size | Experimental group:300;Control group:300 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: